BT-20Homo sapiens (Human)Cancer cell line
Also known as: BT 20, BT20
Quick Overview
Human breast cancer cell line with known p53 mutations and HER2 status.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_0178 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Breast[UBERON:UBERON_0000310] |
Donor Information
Age | 74 |
---|---|
Age Category | Adult |
Sex | Female |
Race | caucasian |
Subtype Features | basal_A TNBC |
Disease Information
Disease | Invasive breast carcinoma of no special type |
---|---|
Lineage | Breast |
Subtype | Breast Invasive Ductal Carcinoma |
OncoTree Code | IDC |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000536_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
MutationSimple | PIK3CA | p.Pro539Arg (c.1616C>G) | Unspecified | - | PubMed=26080861 |
MutationSimple | PIK3CA | p.His1047Arg (c.3140A>G) | Unspecified | - | PubMed=25926053, PubMed=20570890 |
MutationSimple | RB1 | p.Ile388Ser (c.1163T>G) | Homozygous | - | from parent cell line BT-20 |
MutationSimple | RB1 | p.Pro515Leu (c.1544C>T) | Heterozygous | - | from parent cell line BT-20 |
MutationSimple | TP53 | p.Lys132Gln (c.394A>C) | Unspecified | - | from parent cell line Jiyoye |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Human breast tumor cells in culture; new concepts in mammary carcinogenesis.
Lasfargues E.Y., Coutinho W.G.
(In book chapter) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York; USA (1981).
Cell lines from human breast.";
Leibovitz A.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Transplantation of a human mammary carcinoma cell line (BT 20) into nude mice.
Ozzello L., Sordat B., Merenda C., Carrel S., Hurlimann J., Mach J.-P.
J. Natl. Cancer Inst. 52:1669-1672(1974).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
Wolf E., Gabius H.-J.
J. Cancer Res. Clin. Oncol. 127:375-386(2001).
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
Am. J. Clin. Pathol. 117:81-89(2002).
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Genes Chromosomes Cancer 37:29-35(2003).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Cultivation of human breast carcinomas.";
Lasfargues E.Y., Ozzello L.
J. Natl. Cancer Inst. 21:1131-1147(1958).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Chavez K.J., Garimella S.V., Lipkowitz S.
Breast Dis. 32:35-48(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
Molecular characterisation of cell line models for triple-negative breast cancers.
Reis-Filho J.S., Tutt A.
BMC Genomics 13:619.1-619.14(2012).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
The proteomic landscape of triple-negative breast cancer.";
Irie H.Y., Lee S.-I., Blau C.A., Villen J.
Cell Rep. 11:630-644(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).